Viral kinetic changes after 4 weeks and its relation to response to Peg - INF therapy in chronic HCV genotype 4 patients / Ahmed Elsayed Taha Elsayed ; Supervised Gamal Eldin Esmat , Rasha Ahmed Abdelaziz , Dina Sabry Abdelfattah
Material type: TextLanguage: English Publication details: Cairo : Ahmed Elsayed Taha Elsayed , 2014Description: 108 P. : charts ; 25cmOther title:- قياس نسبة التغيرات العددية لفيروس سى بعد الأسبوع الرابع من العلاج بالانترفيرون المقوى فى مرضى الالتهاب الكبدى الوبائى المزمن سى من النوع الرابع [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.33.M.Sc.2014.Ah.V (Browse shelf(Opens below)) | Not for loan | 01010110063772000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.33.M.Sc.2014.Ah.V (Browse shelf(Opens below)) | 63772.CD | Not for loan | 01020110063772000 |
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine
In patients with chronic hepatitis C virus (HCV) infection scheduled for a 48 week treatment period, premature discontinuation of treatment was previously recommended if HCV - RNA levels remained detectable at week 24 of therapy. Considering the number of side effects and treatment costs, measurement of initial viral decline during therapy may identify virologic nonresponse earlier than 24 weeks. To assess changes in the viral load at week 4 of treatment as a predictor for treatment outcome and to update genotype status of HCV. We retrospectively analyzed 152 Egyptian patients treated with pegylated interferon alfa and ribavirin for 48 weeks
Issued also as CD
There are no comments on this title.